Eli Lilly and Company (LLY) Stock: Rebounds as Mounjaro Wins FDA Approval for Cardiovascular Benefits

TLDR Eli Lilly stock rebounds as FDA expands Mounjaro’s cardiovascular approval. Mounjaro wins FDA approval to reduce major cardiovascular risks in diabetes. SURPASS-CVOT showed Mounjaro matched Trulicity on major cardiovascular outcomes. LLY shares recover in premarket trading after the FDA expands Mounjaro’s label. FDA approval strengthens Lilly’s position in diabetes and heart care markets. Eli [...]

The post Eli Lilly and Company (LLY) Stock: Rebounds as Mounjaro Wins FDA Approval for Cardiovascular Benefits appeared first on Blockonomi.